50-166-8586

CSF2 Mouse anti-Human, Clone: OTI6A3, lyophilized, TrueMAB™

Manufacturer: OriGene

Select a Size

Pack Size SKU Availability Price
Each of 1 50-166-8586-Each-of-1 In Stock ₹ 60,342.00

50-166-8586 - Each of 1

₹ 60,342.00

In Stock

Quantity

1

Base Price: ₹ 60,342.00

GST (18%): ₹ 10,861.56

Total Price: ₹ 71,203.56

Antigen

CSF2

Classification

Monoclonal

Conjugate

Unconjugated

Gene

CSF2

Gene Alias

CSF, GMCSF

Host Species

Mouse

Purification Method

Affinity Chromatography

Regulatory Status

RUO

Gene ID (Entrez)

1437

Content And Storage

-20° C, Avoid Freeze/Thaw Cycles

Form

Lyophilized

Applications

Immunohistochemistry (Paraffin), Western Blot

Clone

OTI6A3

Formulation

PBS with 8% trehalose and no preservative; pH 7.3

Gene Accession No.

P04141

Gene Symbols

CSF2

Immunogen

Human recombit protein fragment corresponding to amino acids 18-144 of human CSF2 produced in E.coli.

Quantity

100 μg

Primary or Secondary

Primary

Target Species

Human

Product Type

Antibody

Isotype

IgG1

Related Products

Img

OriGene

50-166-8590

--

Img

OriGene

50-166-8191

--

Img

OriGene

50-166-8193

--

Img

OriGene

50-168-1876

--

Img

OriGene

50-166-5970

--

Img

OriGene

50-168-1864

--

Img

OriGene

50-166-8509

--

Img

OriGene

50-168-1879

--

Description

  • Reconstitute with PBS (pH 7.3) and recommend to perform another round of desalting process using Product No
  • 7KMWCO GM-CSF (Granulocyte-Macrophage colony-stimulating factor) is a 14.6kDa hematopoietic growth factor that exists in glycosylated and non-glycosylated biologically active forms, and stimulates the development of granulocytes, macrophages, early megakaryocytes and eosinophil progenitor cells
  • The active form of the GM-CSF protein is found extracellularly as a homodimer and the GM-CSF gene has been localized to a cluster of related genes at chromosome region 5q31, which is known to be associated with interstitial deletions in the 5q-syndrome and acute myelogenous leukemia
  • Other genes in the cluster include those encoding interleukins 4, 5, and 13
  • The ability of recombit GM-CSF to increase hematopoietic cell recovery has become a focus area in the therapeutic treatment of patients following bone marrow transplantation
  • Recent studies have investigated GM-CSF in inflammatory and autoimmune diseases such as arthritis, arthritis related interstitial lung disease, nephritis, and psoriasis
  • In the CNS, GM-CSF depletion or neutralization has been studied in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS).